Planview and Ozmosi: Bringing AI-Powered Insight to Pharmaceutical Portfolio Decisions
Pharmaceutical organizations are under increasing pressure to make faster, smarter R&D decisions in an environment defined by complexity, uncertainty, and constant change. Making the environment even more vulnerable – and volatile – is the looming “patent cliff” for some of the world’s best-selling drugs, which some analysts predict will trigger up to $350 billion in losses by 2032, according to CNBC.